IP Library Granted Patent US 6,893,655
Granted Patent B2
US 6,893,655 · App. 10/263,413 · Granted May 17, 2005

Transdermal delivery devices

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,893,655
App. No.
10/263,413
Granted
May 17, 2005
Kind
B2
Abstract

A transdermal delivery device including at least one pressure sensitive adhesive layer having a first major surface and a second major surface, wherein at least one of the first and second major surfaces is a structured surface; a cap layer in contact with the structured surface of an adhesive layer; and, at least one medicinal ingredient between the adhesive layer and the cap layer.

Claims (23)

1. A transdermal delivery device comprising at least one pressure sensitive adhesive layer having a first major surface and a second major surface, wherein at least one of the first and second major surfaces is a structured surface; a cap layer in contact with a structured surface of the adhesive layer; and, at least one medicinal ingredient between the adhesive layer and the cap layer; wherein the cap layer in placed in intimate contact with the pressure senstive adhesive and cannot be removed without damage to the adhesive layer.

2. The device of claim 1 , wherein the structured surface of the adhesive layer comprises a plurality of discrete reservoirs, the medicinal ingredient is in the reservoirs, and each reservoir has a void volume of less than about 100 μl.

3. The device of claim 1 , wherein the cap layer is selected from a backing, a membrane, and adhesive layer.

4. The device of claim 1 , wherein the medicinal ingredient is one of a gel, a paste, a foam, a powder, agglomerated particles, microencapsulated liquids, suspensions, liquids, and combinations thereof.

5. The device of claim 1 , wherein the at least one medicinal ingredient comprises, antimicrobial agents, antifungal agents, cosmetic agents, or pharmaceutically effective excipients, and combinations thereof.

6. The device of claim 1 , wherein the medicinal ingredient comprises a drug.

7. The device of claim 6 , wherein the drug is selected from the group consisting of estradiol, testosterone, fentanyl, clonidine, nicotine, or nitroglycerin.

8. The device of claim 1 , further comprising a skin contact pressure sensitive adhesive layer on the adhesive layer on a major surface opposite the cap layer.

9. The device of claim 8 , wherein said cap layer comprises a backing.

10. The device of claim 1 , wherein the cap layer comprises a skin contact pressure sensitive adhesive layer, said transdermal delivery device further comprising a backing on the adhesive layer on a major surface opposite the cap layer.

11. The transdermal delivery device according to claim 2 , wherein at least one reservoir comprises a liquid selected from the group consisting of liquid drugs, drugs dissolved or dispersed in a liquid, skin penetration enhancers, and suitable combinations thereof.

12. The device of claim 8 , further comprising a membrane layer between the adhesive layer and the skin contact pressure sensitive adhesive layer.

13. A method of administering a drug, comprising:

a) providing a transdermal delivery device comprising: at least one pressure sensitive adhesive layer having a first major surface and a second major surface, wherein at least one of the first and second major surfaces is a structured surface, and a cap layer in contact with a structured surface of the adhesive layer, and at least one medicinal ingredient between the adhesive layer and the cap layer;

b) placing the transdermal delivery device upon a patient's skin at an administration site; and

c) maintaining contact with the skin for a time to deliver a therapeutically effective amount of the deliverable/therapeutic composition.

14. A transdermal delivery device, comprising:

(a) a first adhesive layer having a first major surface and a second major surface, wherein at least one of the first and second major surfaces is a structured surface, wherein the first adhesive layer comprises at least one first array of reservoirs, and wherein the first array of reservoirs is at least partially filled with one of air and a first medicinal ingredient; and

(b) a second adhesive layer having a first major surface and a second major surface, wherein at least one of the first and second major surfaces is a structured surface, wherein the second adhesive layer comprises at least one second array of reservoirs, and wherein the second array of reservoirs is at least partially filled with a second medicinal ingredient.

15. The device of claim 14 , wherein the first major surface of the first adhesive layer is a structured surface, and the second major surface of the first adhesive layer is a non-structured surface, and wherein the first major surface of the first adhesive layer contacts a cap layer.

16. The device of claim 15 , wherein the first major surface of the second adhesive layer is a non-structured surface, and the second major surface of the second adhesive layer is a structured surface, and wherein the first major surface of the second adhesive layer contacts the second major surface of the first adhesive layer.

17. The device of claim 14 , wherein the first major surface of the first adhesive layer is a non-structured surface, and the second major surface of the first adhesive layer is a structured surface, and wherein the first major surface of the first adhesive layer contacts a cap layer.

18. The device of claim 17 , wherein the first major surface of the second adhesive layer is a non-structured surface, and the second major surface of the second adhesive layer is a structured surface, and wherein the first major surface of the second adhesive layer contacts the second major surface of the first adhesive layer.

Assignments (4)
SECURITY INTEREST Recorded Dec 14, 2022
From: KINDEVA DRUG DELIVERY L.P.
To: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT
Reel/Frame 062122/0618 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENT COLLATERAL RECORDED AT R/F 053586/0715 Recorded Dec 12, 2022
From: MIDCAP FINANCIAL TRUST, AS ADMINISTRATIVE AGENT
To: KINDEVA DRUG DELIVERY L.P.
Reel/Frame 062115/0707 →
SECURITY INTEREST Recorded Aug 24, 2020
From: KINDEVA DRUG DELIVERY L.P.
To: MIDCAP FINANCIAL TRUST, AS ADMINISTRATIVE AGENT
Reel/Frame 053586/0715 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2020
From: 3M COMPANY; 3M INNOVATIVE PROPERTIES COMPANY
To: KINDEVA DRUG DELIVERY L.P.
Reel/Frame 052818/0234 →